Giá Arch Biopartners Inc. (ACHFF)

Arch Biopartners, Inc. is a portfolio-based biotechnology company, which engages in the development of technologies that have the potential to make a significant medical or commercial impact. The company is headquartered in Toronto, Ontario. The firm is advancing an integrated pipeline that includes new treatments targeting inflammation and toxin-induced kidney injury. Its programs include a pre-clinical chronic kidney disease platform targeting interleukin-32 (IL-32), LSALT peptide, a dipeptidase-1 (DPEP1) inhibitor in Phase II for preventing cardiac surgery-associated acute kidney injury, and cilastatin, a repurposed drug in Phase II for preventing toxin-induced kidney damage. These assets represent distinct, mechanism-based approaches to treating and preventing common causes of kidney damage. Together, they target serious unmet needs in kidney care across both chronic and acute indications, affecting millions of patients worldwide. Its LSALT Peptide and cilastatin, are being developed to target kidney injury caused by inflammation or toxins respectively, which are both significant unmet medical needs.